Navigation Links
InterMune to Release First Quarter Financial Results on April 30
Date:4/21/2009

BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release first quarter 2009 financial results on Thursday, April 30, 2009 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 95970767. To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 95970767.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research program. For additional informa
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... DUBLIN , June 02, 2015 Research ... the "Genotyping Market by Technology, Application & by ... their offering. The global genotyping market is ... Billion in 2015, at a CAGR of 22.3% during ... Market growth will be attributed to the availability of ...
(Date:6/2/2015)... , June 2, 2015   BioClinica ® , ... provider, today announced that David Peters , an ... Executive Vice President and Chief Financial Officer (CFO) and ... Peters brings more than 25 years of financial ... "David has extensive and deep knowledge in all areas ...
(Date:6/2/2015)...  Alere Inc. (NYSE: ALR ), a ... House Antibiotic Stewardship Forum today to announce a ... the President,s National Action Plan to Combat Antibiotic-Resistant ... measurable goals and objectives over the next five ... protect their patients through antibiotic stewardship, slow the ...
(Date:6/2/2015)... New Orleans, LA (PRWEB) June 02, 2015 ... of custom gene synthesis to improve protein expression, announced ... The board includes six executives and entrepreneurs with a ... and software industries. , The team includes: , ... Startup Fund: , Roussel has a background in technology ...
Breaking Biology Technology:Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2BioClinica Names David Peters New Chief Financial Officer 2Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3
... Abstract , Using high ... with differing surface treatment procedures and carbon content levels , ... , Introduction , ... made commercially available that offer optimized properties for select , ...
... , Contaminations of cell cultures show ... production industry. The attention turns here particularly to the prevention , ... or fungi. For companies , that ... a main focus., Endotoxins ...
... Key words: Amino Acids, RP-HPLC, Precolumn derivatisation, o-Phthalaldehyde ... Introduction: , ... significantly absorb light in the UV/visible spectrum. In order ... step in which the amino acids react with a ...
Cached Biology Technology:TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 2TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 3Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 2Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 3Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 4Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 5Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 6Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 7ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION 2ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION 3
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... 2015  Through a well-rounded UAS delegation representing private industry, ... strong showing at AUVSI,s Unmanned 2015 conference last week in ... Ohio,s UAS industry met with over 200 hundred ... along the UAS ecosystem. "Our message is ... for Aerospace Rich Knoll . "If you want to ...
(Date:5/6/2015)... AVIV, Israel , May 6, 2015 ... world,s most established helmet producer, announced today that they ... Smart Helmet, the world,s first bio-sensing cycling helmet and ... be released in two new colors in order to ... for the product. In addition, LifeBEAM and Lazer announced ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Hospital have discovered a new genetic disease that can lead ... bile is missing, the liver cells are exposed to the ... a transformation of liver cells into connective tissue with a ... the cases of liver cirrhosis of unknown origin and open ...
... Meyskens, Jr., M.D., one of the "fathers" of ... to receive the seventh annual American Association for ... in Cancer Prevention Research. The award is ... to the field of cancer prevention research in ...
... Jewish Health have identified a simple gene-based blood test ... response to therapy than current tests. The test, a ... and help clear a backlog of promising medications now ... the results of a small "proof-of-principal" trial in the ...
Cached Biology News:Toxic bile damages the liver 2Meyskens honored with AACR-Prevent Cancer Foundation award 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 3
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
... data analysis , Automatic grid, subgrid and spot ... template assignment , ... Extensive background and signal options to optimize, ... results , Characterize ...
... Agarose and SYBR Safe DNA Gel Stain combo offers ... versus buying these same products separately ... ethidium bromide Eliminates risks ... DNA and RNA fragments from 100 bp to >30 ...
... glycerol stocks contained in standard 96-well microtiter ... with approximately 5,000 clones per plate. After ... well, the corresponding subplate is screened with ... positive well(s). Cells from a positive well ...
Biology Products: